Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bill To Allow FDA To Destroy Counterfeit Devices Wins Praise On Hill; J&J Exec Testifies In Support

Executive Summary

Several US House members are backing a new piece of legislation that would give the US Food and Drug Administration the authority to destroy counterfeit devices when they arrive at points of entry into the country. A Johnson & Johnson executive who specializes in global brand protection provided dramatic testimony before a House health panel on 29 January on the need for the anti-counterfeiting bill.

You may also be interested in...

Congress Gives FDA Authority To Destroy Counterfeit Devices Found In Imports

Safeguarding Therapeutics Act, approved by the House in September and by the Senate on 8 December, targets the proliferation of shipments into the US containing fake testing kits, cures and vaccines that claim to address coronavirus, some available OTC.

US FDA May Destroy Counterfeit Devices Under Bill Awaiting President’s Signature

The US Congress has passed the Safeguarding Therapeutics Act to stop imports of fake medical devices.

US House Panel Passes Telehealth, Counterfeit Device, National Stockpile Bills In Marathon Mark-Up

The House Energy and Commerce Committee swiftly passed three measures impacting medtech companies during a 15 July mark-up session.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts